Literature DB >> 26387944

Inhibition of Super-Enhancer Activity in Autoinflammatory Site-Derived T Cells Reduces Disease-Associated Gene Expression.

Janneke G C Peeters1, Stephin J Vervoort1, Sander C Tan2, Gerdien Mijnheer3, Sytze de Roock3, Sebastiaan J Vastert3, Edward E S Nieuwenhuis4, Femke van Wijk3, Berent J Prakken3, Menno P Creyghton2, Paul J Coffer5, Michal Mokry4, Jorg van Loosdregt6.   

Abstract

The underlying molecular mechanisms for many autoimmune diseases are poorly understood. Juvenile idiopathic arthritis (JIA) is an exceptionally well-suited model for studying autoimmune diseases due to its early onset and the possibility to analyze cells derived from the site of inflammation. Epigenetic profiling, utilizing primary JIA patient-derived cells, can contribute to the understanding of autoimmune diseases. With H3K27ac chromatin immunoprecipitation, we identified a disease-specific, inflammation-associated, typical enhancer and super-enhancer signature in JIA patient synovial-fluid-derived CD4(+) memory/effector T cells. RNA sequencing of autoinflammatory site-derived patient T cells revealed that BET inhibition, utilizing JQ1, inhibited immune-related super-enhancers and preferentially reduced disease-associated gene expression, including cytokine-related processes. Altogether, these results demonstrate the potential use of enhancer profiling to identify disease mediators and provide evidence for BET inhibition as a possible therapeutic approach for the treatment of autoimmune diseases.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26387944     DOI: 10.1016/j.celrep.2015.08.046

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  38 in total

Review 1.  Lingering Questions about Enhancer RNA and Enhancer Transcription-Coupled Genomic Instability.

Authors:  Gerson Rothschild; Uttiya Basu
Journal:  Trends Genet       Date:  2017-01-10       Impact factor: 11.639

2.  Activation of Mouse Tcrb: Uncoupling RUNX1 Function from Its Cooperative Binding with ETS1.

Authors:  Jiang-Yang Zhao; Oleg Osipovich; Olivia I Koues; Kinjal Majumder; Eugene M Oltz
Journal:  J Immunol       Date:  2017-06-21       Impact factor: 5.422

Review 3.  Towards quantitative analysis of gene regulation by enhancers.

Authors:  Ekaterina V Nizovtseva; Stefjord Todolli; Wilma K Olson; Vasily M Studitsky
Journal:  Epigenomics       Date:  2017-08-11       Impact factor: 4.778

4.  Expression of long non-coding RNAs in autoimmunity and linkage to enhancer function and autoimmune disease risk genetic variants.

Authors:  T M Aune; P S Crooke; A E Patrick; J T Tossberg; N J Olsen; C F Spurlock
Journal:  J Autoimmun       Date:  2017-04-15       Impact factor: 7.094

Review 5.  Epigenetic Mechanisms Dictating Eradication of Cancer by Natural Killer Cells.

Authors:  Suresh Bugide; Radoslav Janostiak; Narendra Wajapeyee
Journal:  Trends Cancer       Date:  2018-07-03

Review 6.  Targeting Cancer Cells with BET Bromodomain Inhibitors.

Authors:  Yali Xu; Christopher R Vakoc
Journal:  Cold Spring Harb Perspect Med       Date:  2017-07-05       Impact factor: 6.915

7.  Increased autophagy contributes to the inflammatory phenotype of juvenile idiopathic arthritis synovial fluid T cells.

Authors:  Janneke G C Peeters; Nienke de Graeff; Martin Lotz; Salvatore Albani; Sytze de Roock; Jorg van Loosdregt
Journal:  Rheumatology (Oxford)       Date:  2017-10-01       Impact factor: 7.580

Review 8.  Under-Evaluated or Unassessed Pathogenic Pathways in Autoimmune Hepatitis and Implications for Future Management.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2018-04-18       Impact factor: 3.199

9.  Developmental Control of NRAMP1 (SLC11A1) Expression in Professional Phagocytes.

Authors:  Mathieu F M Cellier
Journal:  Biology (Basel)       Date:  2017-05-03

10.  Hotspots of Aberrant Enhancer Activity in Fibrolamellar Carcinoma Reveal Candidate Oncogenic Pathways and Therapeutic Vulnerabilities.

Authors:  Timothy A Dinh; Ramja Sritharan; F Donelson Smith; Adam B Francisco; Rosanna K Ma; Rodica P Bunaciu; Matt Kanke; Charles G Danko; Andrew P Massa; John D Scott; Praveen Sethupathy
Journal:  Cell Rep       Date:  2020-04-14       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.